DK2176220T3 - Pyrrolidin-2-on-derivater som androgenreceptormodulatorer. - Google Patents

Pyrrolidin-2-on-derivater som androgenreceptormodulatorer.

Info

Publication number
DK2176220T3
DK2176220T3 DK08792430.4T DK08792430T DK2176220T3 DK 2176220 T3 DK2176220 T3 DK 2176220T3 DK 08792430 T DK08792430 T DK 08792430T DK 2176220 T3 DK2176220 T3 DK 2176220T3
Authority
DK
Denmark
Prior art keywords
pyrrolidin
derivatives
androgen receptor
receptor modulators
modulators
Prior art date
Application number
DK08792430.4T
Other languages
Danish (da)
English (en)
Inventor
Atsushi Hasuoka
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of DK2176220T3 publication Critical patent/DK2176220T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
DK08792430.4T 2007-08-07 2008-08-06 Pyrrolidin-2-on-derivater som androgenreceptormodulatorer. DK2176220T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007205966 2007-08-07
JP2007299658 2007-11-19
PCT/JP2008/064500 WO2009020234A2 (en) 2007-08-07 2008-08-06 Pyrrolidin-2 -one derivatives as androgen receptor modulator

Publications (1)

Publication Number Publication Date
DK2176220T3 true DK2176220T3 (da) 2013-06-10

Family

ID=40329363

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08792430.4T DK2176220T3 (da) 2007-08-07 2008-08-06 Pyrrolidin-2-on-derivater som androgenreceptormodulatorer.

Country Status (34)

Country Link
US (2) US8420694B2 (enExample)
EP (1) EP2176220B1 (enExample)
JP (1) JP5292390B2 (enExample)
KR (1) KR20100049644A (enExample)
CN (1) CN101821235B (enExample)
AR (1) AR067823A1 (enExample)
AU (1) AU2008284662B2 (enExample)
BR (1) BRPI0814957B8 (enExample)
CA (1) CA2695852C (enExample)
CL (1) CL2008002313A1 (enExample)
CO (1) CO6160326A2 (enExample)
CR (1) CR11266A (enExample)
CY (1) CY1114067T1 (enExample)
DK (1) DK2176220T3 (enExample)
DO (1) DOP2010000053A (enExample)
EA (1) EA017429B1 (enExample)
ES (1) ES2406685T3 (enExample)
GE (1) GEP20125571B (enExample)
HR (1) HRP20130374T1 (enExample)
JO (1) JO2864B1 (enExample)
MA (1) MA31639B1 (enExample)
ME (1) ME01579B (enExample)
MX (1) MX2010001484A (enExample)
MY (1) MY159910A (enExample)
NZ (1) NZ583624A (enExample)
PE (1) PE20090899A1 (enExample)
PL (1) PL2176220T3 (enExample)
PT (1) PT2176220E (enExample)
RS (1) RS52812B (enExample)
SI (1) SI2176220T1 (enExample)
TN (1) TN2010000062A1 (enExample)
TW (1) TWI418543B (enExample)
WO (1) WO2009020234A2 (enExample)
ZA (1) ZA201001289B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR067823A1 (es) * 2007-08-07 2009-10-21 Takeda Pharmaceutical Compuestos de amina ciclica
WO2009105214A2 (en) 2008-02-22 2009-08-27 Radius Health, Inc. Selective androgen receptor modulators
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
AR071069A1 (es) * 2008-03-26 2010-05-26 Takeda Pharmaceutical Derivados sustituidos de pirazol y su uso para la prevencion o el tratamiento de cancer
EP2531029B1 (en) 2010-02-04 2016-10-19 Radius Health, Inc. Selective androgen receptor modulators
EP3106159A1 (en) 2010-05-12 2016-12-21 Radius Health, Inc. Therapeutic regimens
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
WO2013152170A1 (en) * 2012-04-04 2013-10-10 Catylix, Inc. Selective androgen receptor modulators
EP3158995B1 (en) * 2012-08-09 2018-05-23 Dynamis Therapeutics, Inc. Meglumine for reducing high triglyceride levels
WO2014044357A1 (de) * 2012-09-21 2014-03-27 Merck Patent Gmbh Verbindungen mit einer c-c-dreifachbindung und deren verwendung in flüssigkristallmischungen
FI3122426T3 (fi) 2014-03-28 2023-03-31 Univ Duke Rintasyövän hoitaminen käyttäen selektiivisiä estrogeenin reseptorin modulaattoreita
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
KR101597327B1 (ko) * 2014-04-24 2016-02-24 동아에스티 주식회사 옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제
CN103951688B (zh) * 2014-05-06 2016-04-20 成都安斯利生物医药有限公司 一种制备3,5-二氟-4-甲基苯硼酸的方法
EP3474841B1 (en) 2016-06-22 2022-03-16 Ellipses Pharma Ltd Ar+ breast cancer treatment methods
LT3565542T (lt) 2017-01-05 2024-07-10 Radius Pharmaceuticals, Inc. Polimorfinės rad1901-2hcl formos
JP7473486B2 (ja) 2018-07-04 2024-04-23 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形形態
PE20211733A1 (es) 2019-01-11 2021-09-06 Gruenenthal Chemie Amidas de pirrolidina sustituidas
KR20210127961A (ko) 2019-02-12 2021-10-25 래디어스 파마슈티컬스, 인코포레이티드 방법 및 화합물
CN110204505B (zh) * 2019-05-31 2023-02-03 荆门医药工业技术研究院 (s)-3-苄氧羰基-4-异丙基-2,5-恶唑烷二酮的制备工艺
US20230012570A1 (en) * 2019-11-20 2023-01-19 Medshine Discovery Inc. Bicyclic compound used as selective androgen receptor modulator

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4141399A1 (de) * 1991-12-16 1993-06-17 Bayer Ag 4-(substituierte)amino-3-arylpyrrolinon-derivate
AU754529B2 (en) * 1998-09-22 2002-11-21 Yamanouchi Pharmaceutical Co., Ltd. Cyanophenyl derivatives
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
JP2002088073A (ja) * 2000-09-08 2002-03-27 Yamanouchi Pharmaceut Co Ltd 抗アンドロゲン剤
FR2817472B1 (fr) 2000-12-06 2003-01-03 Oreal Composition de teinture d'oxydation a base de 1-(4-aminophenyl)pyrrolidines substituees au moins en position 2 et 3 et procede de teinture de mise en oeuvre
DK1463497T3 (da) 2001-12-06 2012-01-30 Gtx Inc Behandling af muskelsvind med selektive androgenreceptormodulatorer
JP4316232B2 (ja) 2001-12-28 2009-08-19 武田薬品工業株式会社 アンドロゲン受容体拮抗剤
US20050101657A1 (en) 2001-12-28 2005-05-12 Takeda Chemical Industries Ltd. Androgen receptor antagonists
US7022870B2 (en) 2002-06-17 2006-04-04 University Of Tennessee Research Foundation N-bridged selective androgen receptor modulators and methods of use thereof
EP1553074B1 (en) 2002-08-12 2014-06-18 Takeda Pharmaceutical Company Limited Fused benzene derivative and use
GB0402492D0 (en) 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
US8519158B2 (en) * 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US20080045504A1 (en) * 2004-05-11 2008-02-21 Pfizer Products Inc. Benzonitrile Derivatives to Treat Musculoskeletal Frailty
CA2566942A1 (en) 2004-05-17 2005-12-08 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
PL1753417T3 (pl) 2004-06-07 2012-09-28 Univ Tennessee Res Found Selektywny modulator receptora androgenowego i jego zastosowania medyczne
JP5203712B2 (ja) 2005-01-10 2013-06-05 アカディア ファーマシューティカルズ インコーポレイテッド 選択的アンドロゲン受容体モジュレータとしてのアミノフェニル誘導体
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
ATE412647T1 (de) 2005-05-13 2008-11-15 Lilly Co Eli Substituierte n-arylpyrrolidine als selektive modulatoren des androgenrezeptors
WO2007015567A1 (ja) 2005-08-01 2007-02-08 Takeda Pharmaceutical Company Limited 環状アミン化合物
US20090042857A1 (en) 2006-02-20 2009-02-12 Masuo Yamaoka Novel Pharmaceutical
JP2009543871A (ja) 2006-07-19 2009-12-10 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 選択的アンドロゲン受容体調節薬、その類似体及び誘導体とそれらの使用
AU2007276808A1 (en) * 2006-07-26 2008-01-31 Novartis Ag Inhibitors of undecaprenyl pyrophosphate synthase
EP2098507B1 (en) 2006-11-30 2014-11-12 Takeda Pharmaceutical Company Limited Cyclic amine compound as androgen receptor modulator
AR067823A1 (es) 2007-08-07 2009-10-21 Takeda Pharmaceutical Compuestos de amina ciclica

Also Published As

Publication number Publication date
BRPI0814957B1 (pt) 2019-12-03
HRP20130374T1 (en) 2013-05-31
MA31639B1 (fr) 2010-08-02
MY159910A (en) 2017-02-15
TW200916439A (en) 2009-04-16
PT2176220E (pt) 2013-04-09
PE20090899A1 (es) 2009-08-06
GEP20125571B (en) 2012-07-10
ME01579B (me) 2014-09-20
US20110098336A1 (en) 2011-04-28
CA2695852A1 (en) 2009-02-12
PL2176220T3 (pl) 2013-08-30
CR11266A (es) 2010-03-22
WO2009020234A3 (en) 2009-04-16
DOP2010000053A (es) 2010-07-15
ES2406685T3 (es) 2013-06-07
US7834051B2 (en) 2010-11-16
US20090042967A1 (en) 2009-02-12
TWI418543B (zh) 2013-12-11
CN101821235B (zh) 2012-11-14
KR20100049644A (ko) 2010-05-12
CN101821235A (zh) 2010-09-01
RS52812B (sr) 2013-10-31
TN2010000062A1 (en) 2011-09-26
EA201070246A1 (ru) 2010-08-30
SI2176220T1 (sl) 2013-05-31
ZA201001289B (en) 2011-04-28
AU2008284662A1 (en) 2009-02-12
CY1114067T1 (el) 2016-07-27
US8420694B2 (en) 2013-04-16
MX2010001484A (es) 2010-03-04
NZ583624A (en) 2012-06-29
JO2864B1 (en) 2015-03-15
WO2009020234A2 (en) 2009-02-12
JP5292390B2 (ja) 2013-09-18
EA017429B1 (ru) 2012-12-28
EP2176220B1 (en) 2013-03-27
AU2008284662B2 (en) 2013-07-25
CA2695852C (en) 2017-01-03
BRPI0814957B8 (pt) 2021-05-25
CO6160326A2 (es) 2010-05-20
EP2176220A2 (en) 2010-04-21
JP2010535704A (ja) 2010-11-25
AR067823A1 (es) 2009-10-21
HK1143972A1 (en) 2011-01-21
BRPI0814957A2 (pt) 2015-02-03
CL2008002313A1 (es) 2009-05-15

Similar Documents

Publication Publication Date Title
DK2176220T3 (da) Pyrrolidin-2-on-derivater som androgenreceptormodulatorer.
DK2144897T3 (da) 8-Oxy-quinolinderivater som bradykinin B2-receptormodulatorer
DK2094658T3 (da) Tetrahydrocyclopenta[B]indolforbindelser som androgenreceptormodulatorer
DK2069335T3 (da) Pyridin-3-ylderivater som immunomoduleringsmidler
DK2300465T3 (da) Imidazopyridinderivater som hæmmere af receptortyrosinkinaser
BRPI0907844A2 (pt) moduladores seletivos do receptor de andrógeno
DK2132188T3 (da) Substituerede phenoxy-N-alkylerede thiazolidindioner som østrogenrelaterede receptor-alfa-modulatorer
DK2952177T3 (da) Sammensætninger, der omfatter sphingosin-1-phosphat (s1p)-receptormodulatorer
DK2069336T3 (da) Pyridin-4-yl-derivater som immunomodulerende midler
DK2493858T3 (da) Androgenreceptor modulerende forbindelser.
BRPI0813653A2 (pt) Compostos de imidazotiazol moduladores de sirtuína
DK2195311T3 (da) Pyridinderivater som S1P1/EDG1-receptormodulatorer
BRPI0813651A2 (pt) Compostos de tiazolopiridina moduladores de sirtuína
DK1928845T3 (da) Aminodiazepiner som toll-lignende receptor-modulatorer
DK2224823T4 (da) Pulverformet carotinoidmiddel til farvning af drikkevarer
DK2262808T3 (da) Chemokinreceptormodulatorer
DK2297100T3 (da) Tetrahydrocyclopenta[b]indol-androgenreceptor-modulatorer
DK1984343T3 (da) 2-substituerede benzimidazoler som selektive androgenreceptormodulatorer (SARMS)
BRPI0917446A2 (pt) derivados de acilaminobenzamida.
DK2252609T3 (da) Pyridin-2-yl-derivater som immunomodulerende midler
DK2373652T3 (da) Substituerede piperidin-spiro-pyrrolidinon- og piperidinon-forbindelser anvendt som h3-modulatorer
BRPI0906714A2 (pt) Derivados de oxazepinopirimidona heteroarilamida substituídos.
DK2342182T3 (da) Isoquinolinonderivater som nk3-antagonister
BRPI0822061A2 (pt) Moduladores do receptor canabinoide
DK2094684T3 (da) 1,5-diphenyl-3-benzylamino-1,5-dihydropyrrolidin-2-on som CB1-receptor modulatorer